Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
Primary and acquired resistance of cancer to therapy is often associated with activation of nuclear factor kappa B (NF-κB). Parthenolide (PN) has been shown to inhibit NF-κB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in...
Saved in:
Main Authors: | Malgorzata Sztiller-Sikorska (Author), Malgorzata Czyz (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents
by: Yahui Ding, et al.
Published: (2018) -
Parthenolide as a potential therapeutic agent for gastric cancer: Exploring oxidative stress and DNA damage
by: Shuhong Zeng, et al.
Published: (2024) -
The therapeutic effect and mechanism of parthenolide in skeletal disease, cancers, and cytokine storm
by: Sipin Zhu, et al.
Published: (2023) -
Parthenolide leads to proteomic differences in thyroid cancer cells and promotes apoptosis
by: Meng Cui, et al.
Published: (2022) -
The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
by: An T, et al.
Published: (2022)